Meeting
2023 ASCO Annual Meeting
Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study.
Authors
Hildur Helgadottir
Department of Oncology-Pathology, Stockholm, Sweden
Hildur Helgadottir , Lars Ny , Gustav J. Ullenhag , Johan Falkenius , Rasmus Mikiver , Roger Olofsson Bagge , Karolin Isaksson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9570)
DOI
10.1200/JCO.2023.41.16_suppl.9570
Abstract #
9570
Poster Bd #
333
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.
First Author: Andrew David Knight
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of positive lymph nodes on prognostic stratification in renal cell carcinoma: Analysis of the National Cancer Database.
First Author: Luke Wang
First Author: Jose Pablo Leone
Poster
2020 ASCO Virtual Scientific Program
The impact of census-tract socioeconomic status on survival in stage III colon cancer.
First Author: Amina Dhahri